1. Introduction {#sec1-cancers-11-00431}
===============

MicroRNAs (miRNAs) are small non-coding RNA molecules involved in the regulation of gene expression by partially base-pairing to complementary sequences of target messenger RNAs (mRNA), which leads to cleavage and eventual degradation of the target mRNA or translational repression \[[@B1-cancers-11-00431]\]. The objective of this research is to investigate the potential of using a machine learning approach to validate clinically chosen relevant miRNAs as reliable biomarkers for cancer detection and diagnosis.

Calin et al. \[[@B2-cancers-11-00431]\] were among the first who established the relationship between miRNAs and cancers after discovering that mir15 and mir16 are deleted or down-regulated in a majority of chronic lymphocytic leukemia cases. McManus \[[@B3-cancers-11-00431]\] reviewed examples that link miRNA expression to the development of cancer, and proposed a general role of miRNAs in oncogenesis. Further studies conducted on a variety of cancer types reinforced the causal relationship between miRNA and cancer by demonstrating significantly altered expression profiles of miRNAs in cancer as compared to normal tissue \[[@B4-cancers-11-00431],[@B5-cancers-11-00431],[@B6-cancers-11-00431]\]. It was shown that alteration of only a single miRNA can influence cell identity \[[@B7-cancers-11-00431]\]. These observations led to the increasing interests to test the effectiveness of using miRNAs as biomarkers for diagnosing cancer. However, it has been difficult to identify miRNAs that are clearly important for cancer detection as some miRNAs are up-regulated in certain cancers and function as oncogenes while they are down-regulated in others, acting as tumor suppressors. Furthermore, some miRNAs play pivotal roles in cancer development whereas others are less important. This means that identifying relevant miRNAs will be context-sensitive and dependent on the location and type of cancer that is being considered \[[@B7-cancers-11-00431],[@B8-cancers-11-00431]\]. Therefore, computational analysis of large datasets of miRNA and cancer may greatly improve identification of miRNA biomarkers.

Computational methods, especially machine learning, have been applied for cancer detection and diagnosis using miRNAs as biomarkers. Lu et al. \[[@B5-cancers-11-00431]\] used hierarchical clustering on 73 bone marrow samples and determined that miRNA expression distinguishes tumors of different subtypes within acute lymphoblastic leukemia. They constructed a k-NN classifier using lung cancer samples as well as adjacent healthy samples from mice, which achieved a classification accuracy of 100%. Rosenfeld et al. \[[@B9-cancers-11-00431]\] constructed a miRNA-based tissue classifier to identify the source location of metastatic tumors. By using k-NN and decision trees to classify tumors into 22 different tumor origins (classes), they obtained an accuracy of 89% on the validation set. Prior work was also done by Kotlarchyk et al. \[[@B10-cancers-11-00431]\] on the subject of using feature selection on liver, breast and brain cancer datasets. However, the previous studies were limited by the amount of miRNA data that was readily available and the number of miRNAs that were known at the time. With the emergence of the Genomic Data Commons (GDC) Data Portal provided by the National Cancer Institute, the amount of miRNA expression data increased dramatically. With 34 different types of cancers available, more precise experiments could be performed. Waspada et al. \[[@B11-cancers-11-00431]\] used 22 different miRNA expression datasets from the GDC Data Portal and achieved multiple objectives: (i) a multiclass classification combination of all 22 cancer types, (ii) binary classification using only breast cancer data, (iii) binary classification using breast cancer data with the addition of a feature selection step, and (iv) binary classification with miRNAs selected according to clinical research. Cheerla et al. \[[@B12-cancers-11-00431]\] constructed a SVM-RBF classifier trained with various miRNA expression data across 21 different cancer types, achieving an accuracy of 97.2%. They also used feature selection methods to reduce the number of miRNAs to 60 and still achieved a 95.5% overall classification accuracy. Ali et al. \[[@B13-cancers-11-00431]\] used Neighbourhood Component Analysis to extract relevant miRNA features in order to perform subtype classification, achieving around 95% accuracy. These studies demonstrated the potential of improved cancer detection and diagnosis using miRNAs as biomarkers.

This research aims at using a variety of feature selection techniques to select a subset of miRNAs to identify important miRNA features that are crucial in the diagnosis of breast cancer, a cancer that has accumulated ample amount of miRNA data \[[@B14-cancers-11-00431]\]. The miRBase release 22 (version 22) recorded 1917 confirmed mature human miRNAs \[[@B15-cancers-11-00431]\]. For all practical purposes, it is important to narrow down this large number of miRNAs to find the most discriminative subset of miRNA features for the specific tasks we are working on. Since these miRNAs correspond directly as features, we can employ feature selection methods to remove irrelevant and redundant ones. In machine learning, feature selection is a method of selecting a subset from a given feature set based on a certain set of criteria without transformation of the original features, which preserves the interpretation of the results. This prevents overfitting and improves classification performance especially with gene expression data, which usually has a large number of features. In order to determine the best subset of features, we focus only those miRNAs which have been verified clinically. This allows us to focus on miRNAs that have been deemed relevant in the laboratory. We then apply feature selection methods on this reduced subset of miRNAs to determine which are more important for cancer detection. Even though quite a few miRNAs have been clinically shown to be linked to breast cancer, we aim to show with a machine learning approach that not all miRNAs are equally important as a cancer biomarker, even among those clinically selected ones.

2. Methodology {#sec2-cancers-11-00431}
==============

Our approach for validating clinically selected miRNAs for cancer detection and diagnosis is summarized in [Figure 1](#cancers-11-00431-f001){ref-type="fig"}.

The algorithm is divided into two stages: training and verification. In the training stage, the first step is to clean up the miRNA row data by removing rows with all zero values. We then keep only those miRNAs that have been identified via wet lab as possible biomarkers for breast cancer detection. These biomarkers are classified as clinically verified miRNAs. The list of clinically verified miRNAs identified in the literature is shown in [Table 1](#cancers-11-00431-t001){ref-type="table"}. Three feature selection methods, Information Gain, Chi Squared, and LASSO, are applied to independently rank the importance of miRNAs. The resulting feature vectors are then fed to classification algorithms. For this purpose, two classifiers, Random Forest and Support Vector Machines (SVMs), are applied to train the model. Feature selection is performed on the selected subset of the breast-cancer dataset and these miRNA features are ranked by each feature selection method individually. From these ranked features, different subsets were selected and were then fed into the classification algorithms. The performance of the miRNAs is then evaluated based on certain performance metrics which will be introduced later.

In the next subsections, we discuss the techniques used for both feature selection and classification.

2.1. Feature Selection {#sec2dot1-cancers-11-00431}
----------------------

As has been mentioned before, the objective of feature selection is to identify the specific miRNAs that are most effective in discriminating normal and cancerous tissues. Since the dimensionality of expression data is large in relation to the number of samples, it is easy for classifiers to over-fit, therefore a reduction in feature size will alleviate that problem. Another important aspect of feature selection versus using certain dimensionality reduction techniques, such as Principal Component Analysis, Discrete Cosine Transform and Wavelet Transform, is that we can preserve the original features as opposed to mapping them to a different representation.

In this section, three popular feature selection techniques, Information Gain, Chi-Squared Feature Selection, and Least Absolute Shrinkage and Selection Operator, are reviewed. For a detailed discussion of these methods, readers are referred to \[[@B16-cancers-11-00431],[@B17-cancers-11-00431],[@B18-cancers-11-00431]\].

### 2.1.1. Information Gain {#sec2dot1dot1-cancers-11-00431}

Information Gain (IG) is a feature selection method based on Information Theory, which measures the reduction of entropy that occurs by having knowledge of a feature, *A*. For a dataset *X* with n class labels, the Shannon entropy, which is a measure of unpredictability, is given by the following equation, $$H{(X)} = - \sum\limits_{i = 1}^{n}p_{i}\log_{2}p_{i}.$$ where $p_{i}$ is the probability of class *i* in the data set *X*. IG is the reduction of entropy that is achieved by knowing the feature *A*, shown by the following equation, $$\left. IG(X,A) = H(x) - H(X \middle| A). \right.$$ where, $$H\left. (X \middle| A) \right. = \sum\limits_{i = i}^{v}\frac{X_{i}}{X}H{(X_{i})}.$$ where $X_{i}$ is a subset of *X* containing a distinct value of *A*, *v* is the number of distinct values present in *A* and $H(X_{i})$ is the entropy of the *i*-th subset created by splitting *X* on feature *A*. Therefore, IG can be seen as the difference between the prior entropy and the entropy after splitting the original dataset based on the feature *A*.

### 2.1.2. Chi-Squared Feature Selection {#sec2dot1dot2-cancers-11-00431}

Chi-squared (CHI2) is another feature selection method which evaluates features with respect to the classes. It is a statistical test to determine the dependency of a feature on the class label. We can discard features that do not show dependency and extract the relevant features that are useful for classification. The range of continuous valued features needs to be discretized into intervals. $$\chi^{2} = \sum\limits_{i = 1}^{C}\sum\limits_{j = 1}^{I}\frac{{(A_{ij} - E_{ij})}^{2}}{E_{ij}}$$ where *C* is the number of classes, *I* is the number of intervals, $E_{ij}$ is the expected number of samples, $A_{ij}$ is the number of samples of the $C_{i}$ class within the *j*-th interval. The larger the value of $\chi^{2}$, the more information the corresponding feature provides.

### 2.1.3. Least Absolute Shrinkage and Selection Operator {#sec2dot1dot3-cancers-11-00431}

Least Absolute Shrinkage and Selection Operator (LASSO) is a regularization and variable selection method for statistical models. LASSO minimizes the sum of squared errors while also being subject to a constraint on the sum of the absolute values of the regression coefficients, which is described by, $$\min\limits_{\beta_{0},\beta}\sum\limits_{i = 1}^{N}{(y_{i} - \beta_{0} - x_{i}^{T}\beta)}^{2}s.t.\sum\limits_{j = 1}^{p}\left| \beta_{j} \right| \leq t.$$ where *N* is the number of cases, *p* is the number of features, ($\beta,\beta_{0},\beta_{j}$) are regression coefficients, $y_{i}$ is the *i*-th predicted output and $x_{i}$ is the *i*-th set of features. By tuning the parameter *t*, we can choose the best performing features, as the less predictive coefficients will go to zero.

2.2. Classification {#sec2dot2-cancers-11-00431}
-------------------

After feature selection, one can apply classification algorithms to determine if the target is cancerous or not. In this section, two classifiers, Random Forest and Support Vector Machine (SVM), are overviewed \[[@B11-cancers-11-00431],[@B18-cancers-11-00431]\].

### 2.2.1. Random Forest {#sec2dot2dot1-cancers-11-00431}

The Random Forest (RF) algorithm is an ensemble classifier that generates multiple decision trees, including weak classifiers learned on a random sample from the data. The classification of a new sample is done by majority voting of the decision trees. Random Forest is constructed in the following manner. Assume that the given training set has *N* cases, each with *M* features. Each decision tree is grown as follows: First, *n* samples are selected at random with replacement from the training set. At each node of the tree, $m < < M$ of the features are selected at random. The best split on these *m* features, based on some objective function (for instance, Information Gain), is used to perform a binary split on that node. This process is repeated until a predefined minimum node size is reached. Classification of new data is done through majority votes by aggregating the predictions of all the decision trees.

### 2.2.2. Support Vector Machine {#sec2dot2dot2-cancers-11-00431}

Support Vector Machine (SVM), a supervised machine learning method, aims to design an optimum hyperplane that separates the input features into two difference classes for binary classification. The best solution maximizes the margin, defined by so-called support vectors, between both classes. Given the miRNA data consists of n feature vectors, ($x_{i},y_{i}$), where $y_{i} \in \left\{ + 1, - 1 \right\}$, one can construct an optimization problem in which the distance between the margins is maximized by minimizing the following equation, $$\frac{1}{2}\left| \middle| w \middle| \right|^{2}$$ under the following constraint, $$y_{i}{(wx_{i} + b)} - 1 \geq 0.$$ where *w* is the weights vector which dictates the margin size and *b* is the bias, which shifts the hyperplane boundary. In the case of non-linearly separable data, kernel functions can be used to map the input space to a higher dimensional feature space to allow for a linear separation. A popular kernel function, the Radial Basis Function (RBF), is given as follows: $$k{(x_{i},y_{i})} = \exp\left( {- \left. \gamma \middle| \right|x_{i} - x_{j}{||}^{2}} \right)$$ where $\gamma$ is a hyperparameter that controls the error due to bias and variance. We will use both linear SVM as well as SVM with a radial basis function kernel (RBF) in our experimentation.

3. Results {#sec3-cancers-11-00431}
==========

The microRNA expression dataset for breast cancer was obtained from the National Cancer Institute's Genomic Data Commons Data Portal \[[@B19-cancers-11-00431]\]. This dataset consists of 1207 patient samples with 1881 miRNA features, containing 1103 primary solid tumor samples, 7 metastatic samples and 104 healthy samples. The dataset is imbalanced as there are many more number of cancerous samples compared to healthy samples.

The dataset included raw read counts as well as counts normalized to reads per million mapped reads (RPM). The metastatic samples were combined with the solid tumor samples as one class, since metastatic cancer tissue retained most of the genomic features of the source tumor \[[@B20-cancers-11-00431]\]. The log2 of the RPM values was taken plus a pseudo count of 1 and then the values were standardized to zero mean and unit variance. Zero values were also removed which further reduced the number of miRNA features to 1626. Then miRNAs that were not identified by [Table 1](#cancers-11-00431-t001){ref-type="table"} were removed.

The dataset was run through the classifiers first without feature selection and then with feature selection using different feature selection methods (IG, LASSO and CHI2, see [Section 2.1](#sec2dot1-cancers-11-00431){ref-type="sec"}). In the experiment, we grouped miRNAs into subsets of 3, 5, and 10 members and test their effectiveness in identifying cancer using different feature selection procedures with different classifiers. Also, 10-fold validation was performed throughout. The 10-fold validation is a technique in which in each trial, 90% of the data samples are used for training and the remaining 10% for testing; the process is repeated 10 times, ensuring that all samples are tested once. We chose to only utilize cross-validation and neglect the other steps outlined by the Data Analysis Protocol (DAP), which is outlined by the US-FDA MAQC-II initiative \[[@B21-cancers-11-00431]\]. This is because the focus of this paper is to demonstrate that a small subset of miRNAs can be used to detect cancer with 10-fold validation \[[@B22-cancers-11-00431]\].

Due to the nature of the unbalanced dataset, using only accuracy as a performance metric may misrepresent the performance of our classifiers. In the experiment, we establish the outcomes using the following measures: True positive (TP), False Positive (FP), True negative (TN) and False negative (FN). Here the positive class means a tumorous sample and the negative class is non-cancerous (healthy). Specificity is defined as, $$\frac{TN}{TN + FP}$$ which is the proportion of non-cancerous samples correctly identified. Sensitivity is, $$\frac{TP}{TP + FN}$$ which tests the ability for the cancerous samples to be correctly identified. In addition, Accuracy is simply, $$\frac{TP + TN}{TP + TN + FP + FN}$$ which tests the overall ability to different between healthy and cancerous samples. We also calculate Area Under Curve (AUC).

[Table 2](#cancers-11-00431-t002){ref-type="table"} shows the performance of different feature selection techniques vs different classifiers. In the table, the first column indicates which classifier was used in the experiment. The second one lists the feature selection method along with the number of miRNAs in each group. For instance, IG-10 means that Information Gain is used for feature selection, and miRNAs are grouped into 10 each. Other columns show the performance of the feature selection algorithm teamed up with the classifier.

Examining [Table 2](#cancers-11-00431-t002){ref-type="table"}, we can see that the performance metric that fluctuates the most is the specificity. Since it is possible to achieve a high accuracy even while misclassifying all of the minority class, we need to look at a performance metric that can give us a more meaningful result. Note that the classification accuracy across all selections is practically the same, which confirms its ineffectiveness as a performance metric. The difficulty of this dataset lies in correctly classifying its minority class. We can see a trend of improved sensitivity values when feature selection is used for the RF and SVM-RBF classifiers. This reinforces the notion that there are redundant and irrelevant features present in the dataset and that we may be able to achieve better results with a handful of features rather than the original 1881. We also observed a marked improvement in terms of Specificity by applying any type of feature selection (across all subsets).

Examining the results from [Table 2](#cancers-11-00431-t002){ref-type="table"}, one can also see that even using a small fraction of the entire feature set, one may obtain very good classification results. This means that clinically one may only need to focus on just a few miRNAs to diagnose a patient. In the next section, we ranked the importance of individual miRNAs under different feature selection techniques. [Table 3](#cancers-11-00431-t003){ref-type="table"} show the test results. In this table, miRNAs are ranked in a top-down order under different feature selection algorithms. This means that the miRNAs listed in the top of the table provide better detection performance.

We can see that the subsets of Info Gain and CHI2 are remarkably identical, while overlap six features Lasso, as shown in [Table 3](#cancers-11-00431-t003){ref-type="table"}.

We can also use feature selection to rank those clinically-selected miRNAs. After ranking, we can verify our results by taking different subsets and testing their performance for cancer detection. We begin by choosing the top four miRNA features in subsets of IG and CHI2, ranked 1--3 as Subset \#1. We then slide down by choosing ranked 2--4 miRNAs as Subset \#2, and so on. In this way, we obtain eight different subsets, shown in [Table 4](#cancers-11-00431-t004){ref-type="table"}. We choose four miRNAs as our threshold to mirror our previous experiment as that served as a good limit before performance degradation.

We can now evaluate these data sets with both RF and SVM algorithms. The Specificity has been plotted across the eight subsets, shown in [Figure 2](#cancers-11-00431-f002){ref-type="fig"}.

Interestingly, we observe a downward trend as the subset index (the horizontal axis) goes up, which demonstrates a decrease in classifier performance as we go from Subset \#1 to \#7. The results strongly suggest that miRNAs that are ranked higher are better biomarkers for breast cancer detection than the ones on the bottom in the list.

4. Conclusions {#sec4-cancers-11-00431}
==============

Our results in this work validate clinically-chosen miRNAs as biomarkers for breast cancer detection with a machine learning approach. It demonstrates that by ranking miRNAs using feature selection methods, one is able to determine the best performing miRNAs for breast cancer detection among those clinically verified ones. Our tests have also demonstrated that with merely three selected miRNAs as biomarkers, the classifiers can still produce nearly optimal results in breast cancer detection, in comparison to the use of many more miRNAs.

There are multiple avenues to pursue regarding further work. Specifically, one may extend the framework to identify discriminative miRNAs that indicate different stages of cancer progression if features are available in the datasets. One can also extend these ideas for other cancer types. These other datasets may have common characteristics which can be leveraged using machine learning techniques. With machine learning, one may be able to overcome the problems caused by very small number of samples in cancer datasets. More importantly, the ability of machine learning to classify breast cancer related miRNAs demonstrated here may lead to future development of robotic methods for de novo identification of miRNA biomarkers for other diseases with or without laboratory data.
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cancers-11-00431-t001_Table 1

###### 

Clinically Verified miRNA.

  miRNA \[[@B14-cancers-11-00431]\]                                 
  ----------------------------------- -------------- -------------- ---------------
  hsa-mir-10b                         hsa-let-7d     hsa-mir-206    hsa-mir-34a
  hsa-mir-125b-1                      hsa-let-7f-1   hsa-mir-17     hsa-mir-27b
  hsa-mir-145                         hsa-let-7f-2   hsa-mir-335    hsa-mir-126
  hsa-mir-21                          hsa-mir-206    hsa-mir-373    hsa-mir-101-1
  hsa-mir-125a                        hsa-mir-30a    hsa-mir-520c   hsa-mir-101-2
  hsa-mir-17                          hsa-mir-30b    hsa-mir-27a    hsa-mir-146a
  hsa-mir-125b-2                      hsa-mir-203a   hsa-mir-221    hsa-mir-146b
  hsa-let-7a-2                        hsa-mir-203b   hsa-mir-222    hsa-mir-205
  hsa-let-7a-3                        has-mir-213    hsa-mir-200c   
  hsa-let-7c                          hsa-mir-155    hsa-mir-31     

cancers-11-00431-t002_Table 2

###### 

Performance Metrics across different thresholds of miRNA Features (3, 5, 10).

  Classifier   Method   Accuracy   Sensitivity   Specificity   AUC
  ------------ -------- ---------- ------------- ------------- -------
  RF                    0.996      1.000         0.952         0.999
  IG-10        0.995    0.998      0.962         0.996         
  IG-5         0.996    0.997      0.977         0.998         
  IG-3         0.997    0.997      0.990         0.999         
  CHI2-10      0.995    0.999      0.952         0.995         
  CHI2-5       0.996    0.999      0.979         0.996         
  CHI2-3       0.996    0.997      0.981         0.999         
  LASS-10      0.996    0.998      0.971         0.997         
  LASS-5       0.995    0.997      0.965         0.998         
  LASS-3       0.994    0.997      0.962         0.999         
  SVM-RBF               0.989      1.000         0.875         0.938
  IG-10        0.994    0.998      0.952         0.995         
  IG-5         0.996    1.000      0.990         0.985         
  IG-3         0.998    0.998      0.990         0.980         
  CHI2-10      0.994    0.999      0.951         0.995         
  CHI2-5       0.996    0.998      0.983         0.993         
  CHI2-3       0.998    0.999      0.990         0.980         
  LASS-10      0.995    0.998      0.962         0.996         
  LASS-5       0.995    0.999      0.974         0.985         
  LASS-3       0.996    0.999      0.962         0.980         
  SVM                   0.997      0.999         0.971         0.985
  IG-10        0.997    0.999      0.971         0.997         
  IG-5         0.997    0.999      0.985         0.989         
  IG-3         0.998    0.999      0.990         0.981         
  CHI2-10      0.997    0.999      0.971         0.997         
  CHI2-5       0.996    1.000      0.988         0.987         
  CHI2-3       0.998    0.999      0.990         0.991         
  LASS-10      0.994    0.997      0.962         0.996         
  LASS-5       0.995    0.999      0.956         0.993         
  LASS-3       0.997    1.000      0.962         0.981         

cancers-11-00431-t003_Table 3

###### 

Top Ranked Features Under Different Feature Selection Techniques.

  Info Gain        CHI2             Lasso
  ---------------- ---------------- ----------------
  hsa-mir-10b      hsa-mir-10b      hsa-let-7a-3
  hsa-let-7c       hsa-let-7c       hsa-let-7c
  hsa-mir-145      hsa-mir-145      hsa-let-7d
  hsa-mir-125b-1   hsa-mir-125b-2   hsa-mir-101-1
  hsa-mir-125b-2   hsa-mir-125b-1   hsa-mir-10b
  hsa-mir-335      hsa-mir-335      hsa-mir-125b-2
  hsa-mir-126      hsa-mir-126      hsa-mir-145
  hsa-mir-125a     hsa-mir-125a     hsa-mir-206
  hsa-let-7a-2     hsa-let-7a-2     hsa-mir-27b
  hsa-let-7a-3     hsa-let-7a-3     hsa-mir-335

cancers-11-00431-t004_Table 4

###### 

Subset Selection of Ranked miRNA.

  Subset 1      Subset 2         Subset 3         Subset 4         Subset 5         Subset 6       Subset 7       Subset 8
  ------------- ---------------- ---------------- ---------------- ---------------- -------------- -------------- --------------
  hsa-mir-10b   hsa-let-7c       hsa-mir-145      hsa-mir-125b-1   hsa-mir-125b-2   hsa-mir-335    hsa-mir-126    hsa-mir-125a
  hsa-let-7c    hsa-mir-145      hsa-mir-125b-1   hsa-mir-125b-2   hsa-mir-335      hsa-mir-126    hsa-mir-125a   hsa-let-7a-2
  hsa-mir-145   hsa-mir-125b-1   hsa-mir-125b-2   hsa-mir-335      hsa-mir-126      hsa-mir-125a   hsa-let-7a-2   hsa-let-7a-3
